Century Therapeutics Announces Leadership Changes
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors;…
News
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
MINNEAPOLIS, April 12, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company…
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
MINNEAPOLIS, April 12, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company…
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage…
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage…
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and…
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and…
PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow
Modular panel design sets foundation for continued expansion of applications on the PhenoCycler®-Fusion system First…
Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow
Modular panel design sets foundation for continued expansion of applications on the PhenoCycler®-Fusion system First…
ViCentra to Participate at the upcoming MedTech Strategist Innovation Summit and LSX London Conference
UTRECHT, The Netherlands, April 12, 2023 (GLOBE NEWSWIRE) — ViCentra B.V., the company behind Kaleido,…
ViCentra to Participate at the upcoming MedTech Strategist Innovation Summit and LSX London Conference
UTRECHT, The Netherlands, April 12, 2023 (GLOBE NEWSWIRE) — ViCentra B.V., the company behind Kaleido,…
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
LONDON, April 12, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its…
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
LONDON, April 12, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its…
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company…